Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
Salah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, Gerald Illerhaus, Uwe M Martens, Jan Stoehlmacher, Harald Schmalenberg, Kim B Luley, Nicole Prasnikar, Matthias Egger, Stephan Probst, Helmut Messmann, Markus Moehler, Wolfgang Fischbach, Jörg T Hartmann, Frank Mayer, Heinz-Gert Höffkes, Michael Koenigsmann, Dirk Arnold, Thomas W Kraus, Kersten Grimm, Stefan Berkhoff, Stefan Post, Elke Jäger, Wolf Bechstein, Ulrich Ronellenfitsch, Stefan Mönig, Ralf D Hofheinz, Salah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, Gerald Illerhaus, Uwe M Martens, Jan Stoehlmacher, Harald Schmalenberg, Kim B Luley, Nicole Prasnikar, Matthias Egger, Stephan Probst, Helmut Messmann, Markus Moehler, Wolfgang Fischbach, Jörg T Hartmann, Frank Mayer, Heinz-Gert Höffkes, Michael Koenigsmann, Dirk Arnold, Thomas W Kraus, Kersten Grimm, Stefan Berkhoff, Stefan Post, Elke Jäger, Wolf Bechstein, Ulrich Ronellenfitsch, Stefan Mönig, Ralf D Hofheinz
Abstract
Importance: Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction.
Objective: To evaluate outcome in patients with limited metastatic disease who receive chemotherapy first and proceed to surgical resection.
Design, setting, and participants: The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Patients were enrolled from 52 cancer care centers in Germany between February 1, 2009, and January 31, 2010, and stratified to 1 of 3 groups: resectable (arm A), limited metastatic (arm B), or extensive metastatic (arm C). Data cutoff was January 2012, and the analysis was performed in March 2013.
Interventions: Patients in arm A received 4 preoperative cycles of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) followed by surgery and 4 postoperative cycles. Patients in arm B received at least 4 cycles of neoadjuvant FLOT and proceeded to surgical resection if restaging (using computed tomography and magnetic resonance imaging) showed a chance of margin-free (R0) resection of the primary tumor and at least a macroscopic complete resection of the metastatic lesions. Patients in arm C were offered FLOT chemotherapy and surgery only if required for palliation. Patients received a median (range) of 8 (1-15) cycles of FLOT.
Main outcomes and measures: The primary end point was overall survival.
Results: In total, 238 of 252 patients (94.4%) were eligible to participate. The median (range) age of participants was 66 (36-79) years in arm A (n = 51), 63 (28-79) years in arm B (n = 60), and 65 (23-83) years in arm C (n = 127). Patients in arm B (n = 60) had only retroperitoneal lymph node involvement (27 patients [45%]), liver involvement (11 [18.3%]), lung involvement (10 [16.7%]), localized peritoneal involvement (4 [6.7%]), or other (8 [13.3%]) incurable sites. Median overall survival was 22.9 months (95% CI, 16.5 to upper level not achieved) for arm B, compared with 10.7 months (95% CI, 9.1-12.8) for arm C (hazard ratio, 0.37; 95% CI, 0.25-0.55) (P < .001). The response rate for arm B was 60% (complete, 10%; partial, 50%), which is higher than the 43.3% for arm C. In arm B, 36 of 60 patients (60%) proceeded to surgery. The median overall survival was 31.3 months (95% CI, 18.9-upper level not achieved) for patients who proceeded to surgery and 15.9 months (95% CI, 7.1-22.9) for the other patients.
Conclusions and relevance: Patients with limited metastatic disease who received neoadjuvant chemotherapy and proceeded to surgery showed a favorable survival. The AIO-FLOT3 trial provides a rationale for further randomized clinical trials.
Trial registration: clinicaltrials.gov identifier: NCT00849615.
Conflict of interest statement
Conflict of Interest Disclosures: Dr Al-Batran has an advisory role with Merck, Roche, Celgene, Lilly, and Nordic Pharma; is a speaker for Roche, Celgene, Lilly, and Nordic Pharma; and has received research grants from Sanofi, Merck, Roche, Celgene, Vifor, Medac, Hospira, and Lilly. Dr Arnold has an advisory role with Roche, Bayer, Merck Serono, and Servier, and has received research grants from Roche/Genentech and Sanofi. Dr Ronellenfitsch has received research grants from GSK Oncology and Novartis Oncology. No other disclosures were reported.
Figures
Source: PubMed